Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
0(0%)
Results Posted
20%(3 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
9
50%
Ph phase_4
3
17%
Ph phase_2
2
11%
Ph phase_3
3
17%

Phase Distribution

9

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
9(52.9%)
Phase 2Efficacy & side effects
2(11.8%)
Phase 3Large-scale testing
3(17.6%)
Phase 4Post-market surveillance
3(17.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(15)
Terminated(1)
Other(2)

Detailed Status

Completed15
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (52.9%)
Phase 22 (11.8%)
Phase 33 (17.6%)
Phase 43 (17.6%)

Trials by Status

completed1583%
terminated16%
unknown211%

Recent Activity

0 active trials
Showing 5 of 18
completedphase_1

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

NCT04617782
unknownphase_3

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

NCT03283059
completedphase_1

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

NCT03259958
completedphase_1

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

NCT02968719
completed

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients

NCT02158910
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT04617782Phase 1

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

Completed
NCT03283059Phase 3

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

Unknown
NCT03259958Phase 1

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

Completed
NCT02968719Phase 1

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

Completed
NCT02158910

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients

Completed
NCT00103948Phase 2

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Completed
NCT00165815Phase 3

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Completed
NCT00369603Phase 4

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Terminated
NCT01504503Phase 1

Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition

Completed
NCT01504516Phase 1

Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition

Completed
NCT01439243Phase 1

Donepezil 10 mg Tablets Under Fed Conditions

Completed
NCT01439230Phase 1

Donepezil 10 mg Tablets Under Fasting Conditions

Completed
NCT01245530Phase 3

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

Completed
NCT00230568Phase 4

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

Completed
NCT01260948Phase 1

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

Completed
NCT01260922Phase 1

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

Completed
NCT00018278Phase 4

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

Completed
NCT00031018Phase 2

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Unknown

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18